ArQule Inc. (ARQL)

6.75
0.03 0.44
NASDAQ : Health Technology
Prev Close 6.78
Open 6.81
Day Low/High 6.56 / 6.87
52 Wk Low/High 2.23 / 7.21
Volume 1.71M
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 109.31M
Market Cap 768.45M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On May 15, 2019

ArQule To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On May 15, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr.

ArQule Reports First Quarter 2019 Financial Results

ArQule Reports First Quarter 2019 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter, 2019.

Sinovant Sciences Announces Approval Of Derazantinib's Clinical Trial Application By The China National Medical Products Administration

Sinovant Sciences Announces Approval Of Derazantinib's Clinical Trial Application By The China National Medical Products Administration

ArQule, Inc.'s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the...

ArQule To Report First Quarter 2019 Financial Results On May 1, 2019

ArQule To Report First Quarter 2019 Financial Results On May 1, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2019 before the market opens on Wednesday, May 1, 2019.

Notable Monday Option Activity: ARQL, ASMB, ZAYO

Notable Monday Option Activity: ARQL, ASMB, ZAYO

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ArQule Inc. , where a total of 12,652 contracts have traded so far, representing approximately 1.3 million underlying shares.

ArQule To Present At 18th Annual Needham Healthcare Conference On April 9, 2019

ArQule To Present At 18th Annual Needham Healthcare Conference On April 9, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr.

June 21st Options Now Available For ArQule (ARQL)

June 21st Options Now Available For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading today, for the June 21st expiration.

ArQule Announces Management Team Changes

ArQule Announces Management Team Changes

ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year.

ArQule To Present At Oppenheimer's 29th Annual Healthcare Conference On March 20, 2019

ArQule To Present At Oppenheimer's 29th Annual Healthcare Conference On March 20, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer's 29th Annual Healthcare...

ArQule To Participate In The 31st Annual ROTH Conference On March 17-19, 2019

ArQule To Participate In The 31st Annual ROTH Conference On March 17-19, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in...

ArQule Reports Fourth Quarter And Full Year 2018 Financial Results

ArQule Reports Fourth Quarter And Full Year 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the fourth quarter and full year of 2018.

ArQule Announces Publication Of Clinical Data With Miransertib In Proteus Syndrome

ArQule Announces Publication Of Clinical Data With Miransertib In Proteus Syndrome

ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome.

ArQule To Report Fourth Quarter And Full Year 2018 Financial Results On March 7, 2019

ArQule To Report Fourth Quarter And Full Year 2018 Financial Results On March 7, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019.

ArQule To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ArQule To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.

Basilea Announces Collaboration To Study Derazantinib And Atezolizumab (Tecentriq®) In Urothelial Cancer

Basilea Announces Collaboration To Study Derazantinib And Atezolizumab (Tecentriq®) In Urothelial Cancer

ArQule, Inc.'s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd.

First Week Of ARQL February 15th Options Trading

First Week Of ARQL February 15th Options Trading

Investors in ArQule Inc. saw new options begin trading this week, for the February 15th expiration.

ArQule Added To The NASDAQ Biotechnology Index

ArQule Added To The NASDAQ Biotechnology Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 24, 2018.

ArQule Announces Clinical Data From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies At The 2018 ASH Annual Meeting

ArQule Announces Clinical Data From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies At The 2018 ASH Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK) in...

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60 th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 1 to...

ArQule To Host Analyst Call Highlighting Clinical Progress From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies

ArQule To Host Analyst Call Highlighting Clinical Progress From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company's Phase 1 dose escalation study in patients with relapsed or refractory hematologic...

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60 th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 1 to...

ArQule Presents Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule Presents Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November 13 to 16, 2018 in Dublin, Ireland.

ArQule To Present At The 30th Annual Piper Jaffray Healthcare Conference On November 28, 2018

ArQule To Present At The 30th Annual Piper Jaffray Healthcare Conference On November 28, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on November...

ArQule To Present Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule To Present Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical data on the company's next generation AKT inhibitor, ARQ 751, in three poster presentations at the 30th EORTC/AACR/NCI Symposium to be held from November 13 to...

ArQule Reports Third Quarter 2018 Financial Results

ArQule Reports Third Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018.

ArQule Presents Orphan Disease Clinical Data At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting For Its Pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule Presents Orphan Disease Clinical Data At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting For Its Pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG) 2018 Annual Meeting held from October 16 to 20, 2018 in San...

ArQule To Report Third Quarter 2018 Financial Results On October 31, 2018

ArQule To Report Third Quarter 2018 Financial Results On October 31, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018.

TheStreet Quant Rating: D (Sell)